The Alpha-Gal Syndrome and Hypersensitivity to Biomaterials: Understanding Xenoimmunity.
Academic Article
Overview
abstract
Biomaterials derived from nonhuman mammals are increasingly used in cardiovascular interventions, yet xenoimmune responses to these materials can complicate these procedures. Xenoimmunity describes the immune response mounted against foreign cells, tissues, or organs from different species. Alpha-gal syndrome, a tick-acquired IgE-mediated allergy to galactose-alpha-1,3-galactose, exemplifies this challenge. Patients face risk when exposed to porcine heparin, gelatin-based hemostatic agents, or bioprosthetic heart valves, with reactions ranging from delayed urticaria to immediate anaphylaxis. Alpha-gal sensitization has been linked to accelerated bioprosthetic valve degeneration and increased atherosclerotic plaque burden, suggesting that chronic immune activation may contribute to progressive cardiovascular disease. Cardiovascular hypersensitivity extends beyond alpha-gal syndrome. Drug-eluting stents with polymer coatings and metal alloys can trigger reactions that manifest as late thrombosis and restenosis. Cardiac implantable electronic devices cause hypersensitivity reactions in approximately 2% of recipients through titanium, nickel, and polymer components. Medications including protamine and iodinated contrast can precipitate life-threatening reactions through multiple immunologic pathways. Kounis syndrome and hypersensitivity myocarditis represent the most severe manifestations, where allergic responses directly cause acute coronary events or inflammatory cardiomyopathy. Recognition and prevention require coordinated clinical strategies. Systematic screening in tick-endemic regions helps identify at-risk patients before procedures. Multidisciplinary collaboration between cardiology and allergy specialists enables personalized prophylaxis tailored to sensitization profiles, while emerging diagnostic tools may distinguish benign antibody presence from clinically significant disease. Future progress depends on engineering cardiovascular devices that eliminate xenoantigenic epitopes and developing biomarkers that predict reaction risk. Clinicians must maintain awareness to recognize and prevent immune-mediated complications in susceptible patients.
